Breaking News Instant updates and real-time market news.

ARMK

Aramark

$36.18

0.745 (2.10%)

, CAE

CAE

$19.47

1.02 (5.53%)

10:12
11/14/18
11/14
10:12
11/14/18
10:12

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Aramark (ARMK) upgraded to Outperform from Neutral at Baird analyst Andrew Wittmann citing its recent underperformance, improving free cash flow, roughly 10% earnings growth, synergy benefits, and a steadier business model. 2. CAE (CAE) upgraded to Outperform from Neutral at Macquarie. 3. TD Ameritrade (AMTD) upgraded to Overweight from Equal Weight at Morgan Stanley analyst Michael Cyprys saying he favors discount brokers in a more volatile, late cycle environment. 4. Amarin (AMRN) upgraded to Buy from Neutral at Citi with analyst Joel Beatty citing limited upside to his price target and increased investor expectations. 5. Superior Industries (SUP) upgraded to Buy from Neutral at Buckingham with analyst Glenn Chin saying Q3 results were inline with pre-announced results and the subsequent sell-off is overdone. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ARMK

Aramark

$36.18

0.745 (2.10%)

CAE

CAE

$19.47

1.02 (5.53%)

AMTD

TD Ameritrade

$52.97

1.19 (2.30%)

AMRN

Amarin

$15.17

-0.22 (-1.43%)

SUP

Superior Industries

$8.85

0.15 (1.72%)

ARMK Aramark
$36.18

0.745 (2.10%)

11/14/18
BARD
11/14/18
UPGRADE
Target $44
BARD
Outperform
Aramark upgraded to Outperform at Baird
As reported previously, Baird analyst Andrew Wittmann upgraded Aramark to Outperform from Neutral. The analyst cited its recent underperformance, improving free cash flow, roughly 10% earnings growth, synergy benefits, and a steadier business model. Wittmann maintained his $44 price target and elevated Aramark shares to a Fresh Pick designation.
11/14/18
BARD
11/14/18
UPGRADE
BARD
Outperform
Aramark upgraded to Outperform from Neutral at Baird
10/23/18
BOFA
10/23/18
INITIATION
Target $49
BOFA
Buy
Aramark reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Gary Bisbee reinstated coverage on Aramark with a Buy and $49 price target saying he expects accelerating free cash flow growth and for leverage and other concerns to dissipate over the next year.
09/17/18
09/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Reliance Steel (RS) initiated with a Neutral at Citi. 2. Bausch Health (BHC) assumed with an Overweight at Barclays. 3. Stanley Black & Decker (SWK) initiated with an Outperform at Credit Suisse. 4. Aramark (ARMK) initiated with an Outperform at Bernstein. 5. Kraft Heinz (KHC) was assumed with an Underweight at Morgan Stanley, while Mondelez (MDLZ), General Mills (GIS), and Kellogg (K) were assumed with an Equal Weight. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CAE CAE
$19.47

1.02 (5.53%)

11/14/18
MACQ
11/14/18
UPGRADE
MACQ
Outperform
CAE upgraded to Outperform from Neutral at Macquarie
02/12/18
RBCM
02/12/18
UPGRADE
RBCM
Outperform
CAE upgraded to Outperform from Sector Perform at RBC Capital
AMTD TD Ameritrade
$52.97

1.19 (2.30%)

11/14/18
MSCO
11/14/18
UPGRADE
MSCO
Overweight
TD Ameritrade upgraded to Overweight from Equal Weight at Morgan Stanley
10/04/18
DBAB
10/04/18
NO CHANGE
DBAB
TD Ameritrade, E-Trade oversold into Q3 reports, says Deutsche Bank
Deutsche Bank analyst Brian Bedell sees shares of both TD Ameritrade (AMTD) and E-Trade (ETFC) as oversold heading into the Q3 reporting season. The setup is looking even better for e-brokers into earnings, Bedell tells investors in a research note. With e-broker stocks down a median 9% over the past month, the analyst now "heavily" favors the group within his coverage this earnings season, especially TD Ameritrade and E-Trade. He believes the market is no longer incorporating a meaningful chance of a merger scenario between the two companies. The analyst thinks both stocks can rally on "pure fundamentals."
11/14/18
MSCO
11/14/18
UPGRADE
MSCO
Overweight
Morgan Stanley upgrades TD Ameritrade, favors brokers late cycle
As previously reported, Morgan Stanley analyst Michael Cyprys upgraded TD Ameritrade (AMTD) to Overweight from Equal Weight, stating that he favors discount brokers in a more volatile, late cycle environment. Among the group, TD Ameritrade has the most countercyclical revenue streams, with 27% of revenue tied to trading commissions that tend to spike in volatile environments, Cyprys tells investors. He raised his price target on TD Ameritrade shares to $65 from $61. Cyprys, who also sees growing risk to portfolio harvesting and dividends, lowered his ratings on alternative asset managers Apollo Global (APO) and Carlyle Group (CG), each to Equal Weight.
10/19/18
SBSH
10/19/18
NO CHANGE
SBSH
E-Trade news removes bull case for Ameritrade, Schwab, says Citi
E-Trade (ETFC) last night announced new five-year financial targets and that it will pursue an independent course given higher internal estimates of intrinsic value versus a potential sale, Citi analyst William Katz tells investors in a research note. While the sector has recently sold off, the absence of a sizeable transaction "further removes a bull case thesis" for shares of both TD Ameritrade (AMTD) and Charles Schwab (SCHW), says Katz. Further, he believes the "inaction" also likely leaves open the group to more online pricing pressures and "keeps alive commodization risks." He does not rate E-Trade, has a Neutral rating on Ameritrade and Sell rating on Schwab.
AMRN Amarin
$15.17

-0.22 (-1.43%)

11/14/18
SBSH
11/14/18
UPGRADE
SBSH
Buy
Amarin upgraded to Buy from Neutral at Citi
11/13/18
MAXM
11/13/18
NO CHANGE
Target $5
MAXM
Buy
Matinas BioPharma price target raised to $5 from $2 at Maxim
Maxim analyst Jason McCarthy raised his price target on Matinas BioPharma (MTNB) to $5 and kept his Buy rating after its Q3 results. The analyst adds that he is also factoring in the impact of MAT9001 after the outcome of data evaluating Amarin's (AMRN) Vascepa + Statin, and the company's decision to move MAT9001 forward for hypertriglyceridemia.
11/14/18
SBSH
11/14/18
UPGRADE
Target $28
SBSH
Buy
Citi reverses recent Amarin downgrade, upgrades to Buy after 30% pullback
Citi analyst Joel Beatty upgraded Amarin to Buy from Neutral with an unchanged price target of $28. The stock closed yesterday down 22%, or $4.44, to $15.38. The analyst downgraded the shares to Neutral on November 2 citing limited upside to his price target and increased investor expectations. Beatty, however, believes the 30% pullback in Amarin shares over the past two days following the detailed Reduce-IT trial results creates an attractive entry point. The results "paint an attractive drug profile" for Vascepa, Beatty tells investors in a research note. He continues to predict the drug's peak sales will hit the multi-billions.
11/13/18
CANT
11/13/18
NO CHANGE
Target $35
CANT
Overweight
Physicians not concerned about label for Vascepa, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen said based on her discussions with doctors in attendance at the AHA meeting, she believes the physician community remains "very receptive" to the REDUCE-IT data and noted that "no one" she spoke with seemed concerned about label limitations for Vascepa. Chen also noted that an audience poll during one Continuing Medical Education program showed that nearly all of the physicians in the audience plan to prescribe EPA 4g/day for patients with triglycerides between 200-500 mg/dL. Chen maintains an Overweight rating and $35 price target on Amarin shares.
SUP Superior Industries
$8.85

0.15 (1.72%)

11/09/18
BWSF
11/09/18
DOWNGRADE
BWSF
Hold
Superior Industries downgraded to Hold from Buy at BWS Financial
11/09/18
BWSF
11/09/18
DOWNGRADE
Target $10
BWSF
Hold
BWS downgrades Superior Industries to Hold on 'unfolding negatives'
BWS Financial analyst Vahid Khorsand downgraded Superior Industries to Hold from Buy and lowered his price target for the shares to $8. The company's Q3 included "many unfolding negatives" that are "overshadowing any positive trends," Khorsand tells investors in a research note. It is becoming apparent that management "has a reactionary viewpoint on the business than leading the business through operational challenges that could somewhat have been mitigated," says the analyst. He believes "prolonging needed decisions to cut unnecessary capital outlays could take a toll on the stock price."
11/12/18
RILY
11/12/18
NO CHANGE
Target $20
RILY
Buy
Superior Industries valuation disconnected from potential, at B. Riley FBR
B. Riley FBR analyst Christopher Van Horn lowered his price target for Superior Industries to $20 from $28 saying the 12 month opportunity for shares is lower in light of recent financial headwinds. The analyst, however, keeps a Buy rating on the shares. He continues to believe Superior has a "robust" long-term growth opportunity in aluminum wheels. The valuation after the post-earnings selloff appears disconnected with Superior's long-term potential, Van Horn tells investors in a research note.
11/14/18
BUCK
11/14/18
UPGRADE
Target $12
BUCK
Buy
Superior Industries upgraded to Buy from Neutral at Buckingham
Buckingham analyst Glenn Chin upgraded Superior Industries to Buy from Neutral and lowered its price target to $12 from $19. Chin said Q3 results were inline with pre-announced results and the subsequent sell-off is overdone. The analyst expects higher input costs, lower European production, and high launch costs to subside in future quarters and to continue to benefit from the trend to larger, more complex wheels which tend to be higher revenue and profit/wheel.

TODAY'S FREE FLY STORIES

JMIA

Jumia Technologies

$12.54

-2.15 (-14.64%)

14:18
08/21/19
08/21
14:18
08/21/19
14:18
On The Fly
Citron target Jumia plunges as improper orders on platform put under review »

Shares of Jumia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/21/19
08/21
14:17
08/21/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.08

2.05 (0.71%)

, SPX

S&P 500

$0.00

(0.00%)

14:16
08/21/19
08/21
14:16
08/21/19
14:16
Periodicals
Fed minutes show July cut for insurance for growth, inflation, Bloomberg says »

The interest rate cut…

SPY

SPDR S&P 500 ETF Trust

$292.08

2.05 (0.71%)

SPX

S&P 500

$0.00

(0.00%)

QQQ

Invesco QQQ Trust

$188.29

1.3 (0.70%)

SMH

Market Vectors Semiconductor

$114.29

0.855 (0.75%)

IWM

iShares Trust Russell 2000 Index Fund

$150.29

1.18 (0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/21/19
08/21
14:16
08/21/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
08/21/19
08/21
14:15
08/21/19
14:15
General news
FOMC minutes didn't provide strong clues on the direction of rates »

FOMC minutes didn't…

14:15
08/21/19
08/21
14:15
08/21/19
14:15
General news
FX Action: The dollar »

FX Action: The dollar…

WYND

Wyndham Destinations

$42.79

0.21 (0.49%)

14:11
08/21/19
08/21
14:11
08/21/19
14:11
Hot Stocks
Wyndham Destinations to add 140 jobs in Orlando expansion »

Wyndham Destinations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.47

2.44 (0.84%)

, SPX

S&P 500

$0.00

(0.00%)

14:04
08/21/19
08/21
14:04
08/21/19
14:04
General news
Fed minutes show 'couple of participants' would have preferred 50 bps rate cut »

The minutes for the…

SPY

SPDR S&P 500 ETF Trust

$292.47

2.44 (0.84%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Symbol is now VWAGY

$0.00

(0.00%)

, POAHY

Porsche

$0.00

(0.00%)

14:03
08/21/19
08/21
14:03
08/21/19
14:03
Hot Stocks
Porsche acquires minority stake in Israeli startup TriEye »

Volkswagen's (VLKAY)…

VLKAY

Symbol is now VWAGY

$0.00

(0.00%)

POAHY

Porsche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.42

2.39 (0.82%)

, SPX

S&P 500

$0.00

(0.00%)

14:02
08/21/19
08/21
14:02
08/21/19
14:02
General news
Fed minutes show July rate cut viewed by 'most' on FOMC as 'recalibration' »

The minutes for the…

SPY

SPDR S&P 500 ETF Trust

$292.42

2.39 (0.82%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.06

0.44 (1.27%)

14:01
08/21/19
08/21
14:01
08/21/19
14:01
Hot Stocks
Pfizer says FDA grants XTANDI application priority review »

Astellas Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

TGT

Target

$102.13

16.555 (19.35%)

13:52
08/21/19
08/21
13:52
08/21/19
13:52
Recommendations
Target analyst commentary at Baird »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

JMIA

Jumia Technologies

$12.43

-2.26 (-15.38%)

13:47
08/21/19
08/21
13:47
08/21/19
13:47
Recommendations
Jumia Technologies analyst commentary at Stifel »

Jumia's report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

13:45
08/21/19
08/21
13:45
08/21/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

AFL

Aflac

$49.66

-2.2 (-4.24%)

13:38
08/21/19
08/21
13:38
08/21/19
13:38
Periodicals
Aflac reiterates review being done of Post channel sales, Bloomberg says »

Aflac reiterated that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

, WMT

Walmart

$112.15

0.03 (0.03%)

13:37
08/21/19
08/21
13:37
08/21/19
13:37
Periodicals
Amazon opens 'largest campus yet' in south Indian city, Bloomberg says »

According to an earlier…

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

WMT

Walmart

$112.15

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

  • 14

    Nov

CBL

CBL & Associates

$0.86

0.022 (2.62%)

13:32
08/21/19
08/21
13:32
08/21/19
13:32
Hot Stocks
CBL Properties to pursue measures to cure NYSE rule non-compliance »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
The Food & Drug Law Institute to hold a webinar »

Anthony Anscombe, Partner…

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
FOMC releases minutes from July 30-31, 2019 Policy Meeting »

The Federal Open Market…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/21/19
08/21
13:17
08/21/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

, GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Hot Stocks
YouTube Premium users can now listen directly within Waze app »

In an earlier blog post,…

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$22.31

1.05 (4.94%)

13:06
08/21/19
08/21
13:06
08/21/19
13:06
Hot Stocks
Bausch Health trades up after VP Humphries buys over $650K in shares »

Bausch Health VP William…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

FB

Facebook

$185.03

1.27 (0.69%)

, TWTR

Twitter

$42.65

0.355 (0.84%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
On The Fly
#SocialStocks: New 'Off-Facebook Activity' tool, Argus upgrades Pinterest »

Welcome to…

FB

Facebook

$185.03

1.27 (0.69%)

TWTR

Twitter

$42.65

0.355 (0.84%)

PINS

Pinterest

$36.40

2.05 (5.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

ALXN

Alexion

$113.91

2.49 (2.23%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 02

    Oct

  • 19

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.